Literature DB >> 28990414

Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure.

Ryan McMillan1, Leonidas Skiadopoulos1, Debra Hoppensteadt2, Nil Guler2, Vinod Bansal3, Ravipresenna Parasuraman3, Jawed Fareed2.   

Abstract

The aim of this study was to determine the role of endothelial, renal, and inflammatory biomarkers in the pathogenesis of heart failure (HF) in patients with stage 5 chronic kidney disease (CKD5) undergoing maintenance hemodialysis (HD). Plasma levels of biomarkers-kidney injury molecule 1 (KIM-1), N-terminal pro brain natriuretic peptide (NT-proBNP), glycated hemoglobin, neutrophil gelatinase-associated lipocalin, interleukin-18,platelet-derived growth factor, platelet factor 4 (PF4), 25-OH vitamin D, parathyroid hormone (PTH), endothelin, and endocan-were measured in CKD5-HD patients at the Loyola University Ambulatory Dialysis facility. The HF (+) CKD5-HD patients, as compared to HF (-) CKD5-HD patients, exhibited significantly elevated NT-proBNP ( P = .0194) and KIM-1 ( P = .0485). The NT-proBNP in HF (+) CKD5-HD patients was found to correlate with the levels of serum potassium ( P = .023, R = -.39), calcium ( P = .029, R = -.38), and PF4 ( P = .045, R = -.35). The KIM-1 in HF (+) CKD5-HD patients was found to correlate with PTH ( P = .043, R = -.36) and 25-OH vitamin D ( P = .037, R = .36). Elevated plasma NT-proBNP and KIM-1 in CKD5-HD and HF (+) CKD5-HD patients suggest that natriuretic peptides and KIM-1 may contribute to the pathogenesis of HF in CKD5-HD patients.

Entities:  

Keywords:  HF; chronic kidney disease stage 5; hemodialysis; inflammatory biomarkers

Mesh:

Substances:

Year:  2017        PMID: 28990414      PMCID: PMC6707716          DOI: 10.1177/1076029617729216

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  25 in total

1.  Role of alpha beta receptor heterodimer formation in beta platelet-derived growth factor (PDGF) receptor activation by PDGF-AB.

Authors:  M A Heidaran; J H Pierce; J C Yu; D Lombardi; J E Artrip; T P Fleming; A Thomason; S A Aaronson
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

Review 2.  Uremic platelet dysfunction: past and present.

Authors:  Gines Escolar; Maribel Díaz-Ricart; Aleix Cases
Journal:  Curr Hematol Rep       Date:  2005-09

Review 3.  Endothelin in cardiovascular disease: from atherosclerosis to heart failure.

Authors:  P J Best; A Lerman
Journal:  J Cardiovasc Pharmacol       Date:  2000       Impact factor: 3.105

4.  Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.

Authors:  P M Newman; B H Chong
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

5.  Platelet-derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice.

Authors:  Annica Pontén; Erika Bergsten Folestad; Kristian Pietras; Ulf Eriksson
Journal:  Circ Res       Date:  2005-10-13       Impact factor: 17.367

6.  Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences.

Authors:  Brett Burstein; Eric Libby; Angelino Calderone; Stanley Nattel
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

7.  Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk.

Authors:  Atul Aggarwal; Samer S Kabbani; Jeffery M Rimmer; F John Gennari; Douglas J Taatjes; Burton E Sobel; David J Schneider
Journal:  Am J Kidney Dis       Date:  2002-08       Impact factor: 8.860

Review 8.  The endothelin system and its antagonism in chronic kidney disease.

Authors:  Neeraj Dhaun; Jane Goddard; David J Webb
Journal:  J Am Soc Nephrol       Date:  2006-03-15       Impact factor: 10.121

9.  Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study.

Authors:  Finlay A McAlister; Justin Ezekowitz; Marcello Tonelli; Paul W Armstrong
Journal:  Circulation       Date:  2004-02-09       Impact factor: 29.690

Review 10.  Congestive heart failure in patients with chronic kidney disease and on dialysis.

Authors:  Brian D Schreiber
Journal:  Am J Med Sci       Date:  2003-04       Impact factor: 2.378

View more
  3 in total

1.  Analysis of Different Vascular Accesses on Dialysis Quality and Infection Risk Factors of Hemodialysis Patients.

Authors:  Huaping Wu; Xiang Li; Cunliang Zeng; Li Zhang; Huanhuan Song; Kaiping Lv
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-26       Impact factor: 2.629

2.  Doctor-led intensive diet education on health-related quality of life in patients with chronic renal failure and hyperphosphatemia.

Authors:  Xian-Dong Feng; Xue Xie; Rui He; Fang Li; Gui-Zhong Tang
Journal:  World J Clin Cases       Date:  2022-02-06       Impact factor: 1.337

Review 3.  Prognostic and Diagnostic Value of Endocan in Kidney Diseases.

Authors:  Elisabeth Samouilidou; Virginia Athanasiadou; Eirini Grapsa
Journal:  Int J Nephrol       Date:  2022-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.